Who is sponsoring NCT06135948?

NCT06135948 is sponsored by Emirates Health Services (EHS).

What drugs are being tested in NCT06135948?

Interventions in NCT06135948: Extra dose of L-thyroxine, 25 mcg during Ramadan.

What condition does NCT06135948 study?

NCT06135948 studies L-thyroxine.

Is NCT06135948 still recruiting?

NCT06135948 is currently completed. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT06135948

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Increasing Levothyroxine Dose in Ramadan for UAE Patients With Hypothyroidism

Completed Phase 4 Last updated 18 November 2023

What this trial tests

Phase 4 trial testing Extra dose of L-thyroxine, 25 mcg during Ramadan in L-thyroxine in 103 participants. Completed in 15 June 2022.

Timeline

15 March 2022

Primary endpoint
15 June 2022

15 June 2022

Quick facts

Lead sponsor	Emirates Health Services (EHS)
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	103
Start date	15 March 2022
Primary completion	15 June 2022
Estimated completion	15 June 2022
Sites	1 location across United Arab Emirates

Drugs / interventions tested

Extra dose of L-thyroxine, 25 mcg during Ramadan — full drug profile →

Conditions studied

L-thyroxine — all drugs for L-thyroxine →

Sponsor

Emirates Health Services (EHS) — full company profile →

Who can join

Adults 18 to 70, any sex, with L-thyroxine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to compare the mean change in Thyroid Stimulating Hormone (TSH) levels among patients with hypothyroidism treated with an increased dose of L-thyroxine (treatment group) versus standard/regular dose of L-thyroxine (control group) during the month of Ramadan.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Emirates Health Services (EHS) trials

Trials by the same sponsor.

NCT07395583 — Preventing Non-Contact Hamstring Injuries in Elite Footballers: Eccentric vs Concentric Training · NA · active not recruiting
NCT07115316 — EFFECTIVENESS OF ECCENTRIC HAMSTRING CONTRACTIONS WITH PHYSIOTHERAPY TRAINING ON SPORTS PERFORMANCE AND QUALITY OF LIFE · NA · recruiting
NCT05705388 — POSE2.0 With GLP-1 Agonist for Obesity Management · NA · unknown
NCT05144178 — Insight Into the UAE Experience With Monoclonal Antibodies (Sotrovimab ) · unknown
NCT05611567 — Endoscopic Gastric Plication Using the POSE2.0 Technique for Management of Fatty Liver Disease · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06135948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emirates Health Services (EHS)
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06135948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing